Xerostomia
Drug research and approvals for xerostomia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 73 studies of xerostomia are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, and FDA has 3 approved and 3 open orphan designations naming it.
- Recruiting worldwide: 73
- Trials authorized in Canada: 4
- FDA orphan approvals: 3
- EU medicines: 0
- Evaluation of the Prevalence, and Immunological Characteristics of Small Fiber Neuropathy in Patients With Primary…NCT07917442 · Not applicable · Centre Hospitalier Universitaire, Amiens · starts Mar 31, 2026
- Oral Care Program for Mouth Side Effects During Head and Neck Radiation TherapyNCT07885033 · Not applicable · UNCANCER LLC · starts Nov 1, 2026
- Effect of the Dietary Supplement to Alleviate Dry Mouth.NCT07847840 · Not applicable · Lacer S.A. · starts Oct 5, 2026
- Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung DiseaseNCT07843381 · Not reported · Peking University People's Hospital · starts May 1, 2026
- Pain Phenotyping of Rheumatic Diseases - An Observational StudyNCT07829497 · Not reported · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · starts Nov 9, 2026
- A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's DiseaseNCT07737743 · Phase 2 · Novartis Pharmaceuticals · starts Aug 24, 2026
- A Study of ATG-201 in Adult Participants With Autoimmune DiseasesNCT07732309 · Phase 1 · Antengene Biologics Limited · starts Sep 26, 2026
- A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic DiseasesNCT07712939 · Phase 1 · Candid Therapeutics · starts Jul 22, 2026
- Foot Reflexology and Ta-VNS for Symptom Management in Head and Neck Cancer During CCRTNCT07711626 · Not applicable · Tzu Chi University · starts Jul 13, 2026
Approved 3
- PilocarpineMuscarinic acetylcholine receptor M3 agonist
- CevimelineMuscarinic acetylcholine receptor M3 agonist
- AmifostineReactive metabolite scavenging agent
Phase 3 6
- BetaineBetaine-homocysteine S-methyltransferase substrate
- Honey
- Xylitol
- Taurine
- Myeloperoxidase
- Lysozyme chloride
Phase 2 2
- DexamethasoneGlucocorticoid receptor agonist
- OxygenEssential for cellular homeostasis
Phase 1 or earlier 3
- CisplatinDNA inhibitor
- Interferon gamma-1bInterferon gamma receptor agonist
- D-limonene
How its trials ended
225 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 35 whose ending is known, 51% met their primary endpoint, 6% missed it and 43% stopped early.
- Completed, result not reported11752%
- Ongoing4520%
- Status unknown2812%
- Met its primary endpoint188%
- Stopped: other or unclear84%
- Stopped: enrollment or feasibility31%
- Missed its primary endpoint21%
- Stopped: funding21%
- Stopped: lack of efficacy1<1%
- Stopped: sponsor or business decision1<1%
| Feb 3, 2026 | Pretherapy botulinum toxin to reduce radiation-related xerostomia in head and neck cancerBotox | Research Institute of The McGill University Health Centre | Pending |
| Mar 7, 2025 | Long-term follow-up of AAV2-HAQP1 gene therapy in participants with radiation-induced late xerostomiaAAV2-HAQP1 | MeiraGTx Holdings | Ongoing |
| Sep 29, 2023 | A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of AAV2-HAQP1 gene therapy in participants with radiation-induced…AAV2-HAQP1 | MeiraGTx Holdings | Ongoing |
| Feb 28, 2020 | "a phase 1/2 open-label, dose escalation study to determine the optimal dose, safety, and efficiacy of AAV2HAQP1 in subjects with radiation-induced parotid…AAV2HAQP1 | MeiraGTx Holdings | Pending |
| Jun 24, 1999 | EthyolReduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck… | Medimmune Oncology, Inc. | Approved |
| Feb 11, 1998 | SalagenTreatment of dry mouth in patients with Sjogren's syndrome. | MGI Pharma, Inc. | Approved |
| Mar 22, 1994 | SalagenTreatment of symptoms of xerostomia from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck. | MGI Pharma, Inc. | Approved |
| May 3, 2013 | Replication-deficient recombinant serotype 2…Treatment of symptoms of Grade 2 and Grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral… | MeiraGTx, LLC | Designated |
| Jul 31, 2001 | Intraoral fluoride releasing systemPrevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer | Digestive Care, Inc. | Designated |
| Dec 20, 1999 | Recombinant human keratinocyte growth factorReducing the incidence and severity of radiation-induced xerostomia. | Swedish Orphan Biovitrum AB (publ) (SOBI) | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA